U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N3S
Molecular Weight 209.3127
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALIPEXOLE

SMILES

C=CCN1CCc2c(CC1)sc(=N)[nH]2

InChI

InChIKey=DHSSDEDRBUKTQY-UHFFFAOYSA-N
InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)

HIDE SMILES / InChI

Molecular Formula C10H15N3S
Molecular Weight 209.3127
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

Originator

Curator's Comment:: # Boehringer Ingelheim Pharma KG

Approval Year

PubMed

PubMed

TitleDatePubMed
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
2001 Apr 6
Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.
2001 Aug
Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.
2001 Feb 16
Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
2001 Jan-Feb
[A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
2001 May
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.
2001 May
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
2001 May 1
Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat.
2001 Nov-Dec
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.
2001 Oct
Alpha2-adrenoceptor ligands inhibit alpha1-adrenoceptor-mediated contraction of isolated rat arteries.
2002 Aug
Influence of sildenafil on central dopamine-mediated behaviour in male rats.
2002 Feb 15
Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models.
2002 Jan
Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed rat.
2002 Mar
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.
2003
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
2003 Apr
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.
2003 Aug
Prolonged drug-induced hypothermia in experimental stroke.
2003 Mar-Apr
Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.
2004 Apr 5
Immunohistochemical and functional evidence for a noradrenergic regulation in the horse penile deep dorsal vein.
2004 Dec
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004 May 1
Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.
2004 May 1
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
2004 Oct 11
Drug treatment of Parkinson's disease.
2004 Sep
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.
2006
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.
2007
alpha2-adrenoceptor agonists as nasal decongestants.
2007
MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.
2007 Sep
Pharmacological modulation of dopaminergic brain activity and its reflection in spectral frequencies of the rat electropharmacogram.
2008
Mechanism of decongestant activity of alpha 2-adrenoceptor agonists.
2008
Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
2008 Apr 30
Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
2008 Feb 15
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
2008 Mar
The frequency of cardiac valvular regurgitation in Parkinson's disease.
2008 May 15
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
2008 Nov 19
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
2009 Feb
Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury.
2009 Jan-Mar
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
2009 Jun
Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
2009 Nov 5
The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells.
2010 Dec
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.
2010 May
[Dopaminergic neuroprotection and reconstruction of neural network tiara].
2010 Oct
Patents

Patents

Sample Use Guides

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day)
Route of Administration: Oral
In Vitro Use Guide
Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:18:08 UTC 2021
Edited
by admin
on Sat Jun 26 14:18:08 UTC 2021
Record UNII
7AM2J46Z1Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALIPEXOLE
INN   MI   WHO-DD  
INN  
Official Name English
6-ALLYL-2-AMINO-5,6,7,8-TETRAHYDRO-4H-THIAZOLO(4,5-D)AZEPINE
Systematic Name English
TALIPEXOLE [INN]
Common Name English
TALIPEXOLE [MI]
Common Name English
TALIPEXOLE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
Code System Code Type Description
MERCK INDEX
M10441
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
TALIPEXOLE
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
EVMPD
SUB10805MIG
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
DRUG CENTRAL
2558
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
MESH
C024763
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
FDA UNII
7AM2J46Z1Y
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
PUBCHEM
5374
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
CAS
101626-70-4
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
NCI_THESAURUS
C152496
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
EPA CompTox
101626-70-4
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL279085
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
INN
5973
Created by admin on Sat Jun 26 14:18:08 UTC 2021 , Edited by admin on Sat Jun 26 14:18:08 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY